Get the Stockscreener App
0.6899
2.97%
0.0199
After Hours:
.67
-0.0199
-2.88%
Genenta Science Spa Adr stock is traded at $0.6899, with a volume of 113.52K.
It is up +2.97% in the last 24 hours and up +2.18% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
See More
Previous Close:
$0.67
Open:
$0.6775
24h Volume:
113.52K
Relative Volume:
1.22
Market Cap:
$16.28M
Revenue:
-
Net Income/Loss:
$-7.33M
P/E Ratio:
-1.8581
EPS:
-0.3713
Net Cash Flow:
$-8.02M
1W Performance:
-2.14%
1M Performance:
+2.18%
6M Performance:
-69.87%
1Y Performance:
-83.77%
1-Day Range:
$0.6209
$0.6999
1-Week Range:
$0.6209
$0.76
52-Week Range:
$0.59
$10.00
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
0.6899 | 15.81M | 0 | -7.33M | -8.02M | -0.3713 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Resumed | ROTH MKM | Buy |
| Jul-25-22 | Initiated | H.C. Wainwright | Buy |
| Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
Genenta Science to close US subsidiary and transition CFO to consulting role - Investing.com Canada
Genenta Science to close US subsidiary and transition CFO to consulting role By Investing.com - Investing.com South Africa
Genenta Science to Close U.S. Subsidiary and Shift CFO to Consulting Role - TipRanks
Genenta Science Moves Into Aerospace With Majority Investment Deal for Sòphia High Tech - The Globe and Mail
GNTA Stock Price, Quote & Chart | GENENTA SCIENCE SPAADR (NASDAQ:GNTA) - ChartMill
Genenta signs Definitive Agreements with Sophia High Tech - GlobeNewswire Inc.
Genenta Science Warned by Nasdaq Over Minimum Bid Price Compliance - The Globe and Mail
Genenta Science receives Nasdaq notice on minimum bid price compliance By Investing.com - Investing.com India
Genenta Science receives Nasdaq notice on minimum bid price compliance - Investing.com
What's going on in today's pre-market session - chartmill.com
Genenta Moves to Acquire Control of Italian Space-Defense Supplier Sòphia High Tech - TipRanks
Genenta Science Cancels Late-March Vote on Rebrand to Saentra Forge - The Globe and Mail
Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business - Finviz
11 Best Italian Stocks to Buy in 2026 - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Prenetics Group (PRE) - The Globe and Mail
Genenta Science Piv A Strategic Shift from Biotech to Defense - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Genenta Science stock soars on strategic pivot to defense sector By Investing.com - Investing.com Australia
Genenta Science stock soars on strategic pivot to defense sector - Investing.com
Genenta to Rebrand as Saentra Forge and Pivot into Italian National-Security Industrial Consolidator - TipRanks
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and BioLife Solutions (BLFS) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Trading Up 0.7% – Here’s What Happened - Defense World
Operating cash flow per share of Genenta Science SpA Sponsored ADR – FWB:K5F - TradingView — Track All Markets
Return on equity % of Genenta Science SpA Sponsored ADR – LSX:A3C9EK - TradingView
Healthy Upside Potential: Genenta Science SpA ADR (GNTA) - Setenews
Genenta Science stock soars after update on glioblastoma treatment study By Investing.com - Investing.com Australia
Genenta Science stock soars after update on glioblastoma treatment study - Investing.com
Genenta Science (NASDAQ:GNTA) Shares Down 3.4% – Should You Sell? - Defense World
Candlestick signals on Genenta Science S.p.A. Depositary Receipt stock todayProduct Launch & Short-Term Trading Opportunity Alerts - newser.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX) - The Globe and Mail
Genenta Science Expands Board and Corporate Purpose Following Shareholders’ Meeting - MSN
Genenta Science Secures $15 Million in Registered Direct Offering - The Globe and Mail
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - inkl
Genenta Science Appoints New Board Member and Confirms CEO - The Globe and Mail
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.71% - Investing.com UK
These stocks are moving in today's pre-market session - ChartMill
Genenta Science Soars Following Strategic Collaboration with Anemocyte - StocksToTrade
Genenta Science Stock Skyrockets After Strategic Collaboration Announcement - StocksToTrade
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
Genenta Science Reports Reduced Losses and Strengthened Balance Sheet for H1 2025 - TipRanks
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - The Globe and Mail
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):